Millions of Americans who rely on low-cost prescription medications imported from Canada could soon lose access due to a new U.S. Customs and Border Protection rule taking effect later this month. The policy shift has triggered strong pushback from lawmakers across party lines as the rising cost of living remains a critical concern for voters ahead of upcoming midterm elections.
While the regulation targets a wide range of imported goods to enforce tariffs and curb illegal drug trafficking, healthcare advocates warn that its stricter requirements—including mandatory bond guarantees and additional data filings—will severely disrupt the delivery of personal prescriptions. Many patients have already seen prices climb following preliminary customs policy changes in August 2025, and the upcoming October 22 compliance deadline threatens to halt personal prescription imports entirely.
